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A systematic review of pre-clinical studies on the effects of cannabidiol 
on breast cancer cells 
 
Abstract 
The aim of this systematic review is to determine the effects of cannabidiol on breast 
cancer cells in pre-clinical studies. A search was conducted in nine databases for pre-
clinical studies that have examined the effect of CBD on breast cancer. Thirteen studies 
were found to have met the inclusion and exclusion criteria. The full texts were then read 
and assessed using the inclusion and exclusion criteria. Six studies met the inclusion and 
exclusion criteria – these included three in vitro studies and 3 mixed studies. The in vitro 
components of the studies were assessed for quality via the modified CONSORT 
checklist, and the in vivo (animal) component was assessed via the ARRIVE guidelines. 
The majority of articles were poorly reported, specifically regarding the in vivo 
components of the mixed studies. Higher quality studies are required with improved 
reporting. Unfortunately there have currently been no clinical trials conducted on the 
effects of CBD on breast cancer and the related literature is limited. CBD has been shown 
to have anti-tumour effects on multiple breast cancer cell lines in in vitro and mixed 
studies. More research is needed in this field as CBD may prove to be an anti-cancer 
therapy with a low side-effect profile. 
 
 
1. Introduction 
 
Breast cancer is the term used for a malignant tumour which has developed from cells in 
the breast. It mainly affects females over the age of 45, but can also affect men. After 
skin cancer, invasive breast cancer is the most frequently diagnosed cancer in women in 
the United States of America, affecting 12.4% of women (American Cancer Society, 
2017). In South Africa it affects 30.52% of women, making it the most prevalent cancer. 
It is also the second leading cause of cancer-related deaths in women (National Cancer 
Registry, 2012). The mortality rate is 22% in the first 5 years of being diagnosed with 
stage IV breast cancer (American Cancer Society, 2016). The conventional treatment 
options for breast cancer include surgery, radiation therapy, chemotherapy, hormone 
therapy and targeted therapy. Treatment is often radical and results in unwanted side 
effects. These may include a loss of breast tissue, lymphoedema, nausea, vomiting, 
chronic pain, hair loss, chronic fatigue, increased susceptibility of developing other 
cancers and increased possibility of infection (National Cancer Institute, 2016).  
 
CBD is a cannabinoid derived from the Cannabis sativa plant (Elbaz et al., 2015). After 
THC, CBD is the most abundant active ingredient and is the major non-psychoactive 
cannabinoid (McAllister et al., 2015). CBD is produced via non-enzymatic 
decarboxylation of cannabidiolic acid when extracted from the plant material (Takeda et 
al., 2012). Recent studies have found cannabidiol to have anti-tumour and anti-metastatic 
effects, specifically in aggressive breast cancer, by acting as an antagonist on the CB1 
receptor and as an inverse agonist on the CB2 receptor, which are part of the 
endocannabinoid system (Murase et al., 2014).  
 
A systematic literature review is used to critically identify, analyse and appraise past 
research studies, based on a single research question, by using several database searches. 
The studies are then interpreted and presented objectively (Saltikov, 2010). A systematic 
literature review will differentiate poor quality studies from high quality studies, thus 
offering high quality data. This further adds to evidence-based medicine, which assists in 
evidence-based practice (Brown et al., 2012). 
 
This systematic review sourced articles from a multitude of online databases dating from 
the year 2000 to 2017. Appropriate search terms were used in order to identify the most 
relevant research related to this topic. All studies focused on the effects of CBD on breast 
cancer in pre-clinical studies.  
 
Although more research needs to be conducted in this field, CBD may be a promising 
treatment for breast cancers. Currently there has not been a systematic review conducted 
on this subject. By doing so it will allow for a comprehensive review of the effects of 
CBD in breast cancer and aid in its understanding and further research 
 
The aim of the systematic review was to investigate and provide a summary and analysis 
of research that has been conducted on the effects of cannabidiol on breast cancer in pre-
clinical studies. 
 
This study is a review of current available literature on CBDs effect on breast cancer cells 
in pre-clinical studies. It may also open up research into other aspects of cannabis and 
cancer treatment and research, or the potential use of CBD as an alternative anti-cancer 
treatment.  This review may benefit healthcare practitioners, patients, educators and 
researches. 
 
2. Methods 
2.1 Research design and identifying relevant research 
The review was based on electronic journal articles and journals sourced from online 
databases. The following online databases were used to source the relevant research 
articles: 
• Pubmed 
• Science Direct 
• Springer Link 
• Ujoogle 
• Google scholar 
• Scopus 
• Academic Search Complete 
• Lexis Nexus Academic 
• Proquest 
 
The search terms that were used to source the relevant research articles were as follows: 
“Cannabidiol,” “CBD,” “Cannabis,” “breast cancer,” “carcinoma,” “carcinoma in situ,” 
“hemp oil,” and “tumour.” These terms were used by themselves and in multiple 
combinations and different orders. Articles were evaluated for relevance by means of 
inclusion and exclusion criteria, and title and abstract were utilized. A log was kept of 
studies that were included and excluded as well as the reasons for doing so.  
 
2.1.1 The research question 
Does cannabidiol have an effect on breast cancer in pre-clinical studies? 
  
2.1.2 Inclusion criteria 
The journal articles used in the review had reference to the treatment of breast cancers 
with cannabidiol in pre-clinical studies. This included pre-clinical trials such as in vitro 
and in vivo studies, mixed studies trials and comparative studies. The studies chosen 
were published between 2000 and 2017. All studies sourced were in English. 
 
2.1.3 Exclusion criteria 
Journal articles that did not reference the treatment of breast cancer with cannabidiol 
were excluded. Duplicate studies were excluded. Articles published prior to 2000 were 
excluded. The modified CONSORT checklist for in vitro studies; and the ARRIVE tool 
for animal studies were used to assess the quality of the studies, poor quality studies were 
excluded. 
 
2.2 Assessing the quality of the studies 
The studies chosen after evaluation for inclusion were assessed via the modified 
CONSORT checklist for in vitro studies; and the ARRIVE tool for animal studies, in 
order to determine the quality, reliability and validity of the studies chosen.  
 
2.3 Data collection, integration and interpretation of the findings 
The first phase of data collection involved the author reviewing the titles and abstracts of 
the studies found. These were then objectively assessed. Those found to be within the 
guidelines of the inclusion and exclusion criteria were chosen for phase two.  In phase 
two the full texts were read and a conclusion based on inclusion and exclusion criteria 
was reached for inclusion of the study in this review.  If there were any uncertainties as to 
the inclusion of a study, the supervisor intervened to reach a consensus by means of 
discussion and mutual agreement. 
 
Data was then extracted from the studies which included: year, author, the aim, study 
design/methodology, and the outcome. Information from the studies was individually 
summarised as well as put into a table format which allowed for comparisons between 
studies. 
 
Journal articles with consistent findings and similar methodologies were combined, while 
those with conflicting findings were distinguished and separated. The data was collected 
and graphically represented via tables for ease of interpretation. The findings were 
interpreted and conclusions were made based on the analysis of the chosen articles. 
 
2.4 Reliability and Validity 
The consolidated standards of reporting trials (CONSORT) checklist is used to assist 
researchers in the reporting of clinical trials as well as enabling readers to assess the 
validity of the research conducted. This checklist uses 25 items which cover all aspects of 
clinical trials (Moher et al, 2010). Currently a standard method to assess the reliability 
and quality of an in vitro study for the purposes of a systematic review does not exist. 
The CONSORT tool has been modified in order to adapt it to assess in vitro studies with 
regards to systematic reviews by Faggion Jr, (2012). In this article the CONSORT 
checklist was adapted to evaluate the quality as well as the risk of bias in in vitro studies 
on dental materials (Faggion Jr, 2012; National Research Council, 2014). The modified 
CONSORT checklist was used in this review to assess in vitro studies and mixed studies.  
 
The Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines is a tool 
used to improve the reporting of animal studies. The guidelines are suited for any area of 
research that uses animals for pre-clinical studies. The ARRIVE guidelines were used to 
assess the quality of animal study design (Kilkenny et al, 2010).  
 
 
2.5 Ethical considerations 
Only recently published, peer-reviewed studies were used for this review. The studies 
chosen were required to have been assessed by an independent ethics committee and 
found to be non-plagiarised. All studies were sourced from accredited databases. In order 
to prevent bias, multiple references from the same author were avoided and duplicate 
studies were omitted. Non-bias was ensured by the author while analysing the data from 
the studies chosen. A record of included and excluded studies and sources was kept to 
ensure non-plagiarism. The studies chosen were reviewed by the researcher and one 
supervisor to reach consensus on which studies were to be included. Studies were also 
reviewed by the researcher and the supervisor independently of each other. If a 
disagreement occurred a third reviewer was consulted when necessary. When interpreting 
and extracting the data the author ensured it was represented as identical to the original 
work. A precise method was used to cite literature and the authors were correctly 
acknowledged. Unethical and biased studies were excluded from this review. 
 
3. Results 
3.1 Identification of studies 
A comprehensive search was conducted for all pre-clinical English articles, published 
between the years 2000 to 2017, relating to the effects of cannabidiol (CBD) on breast 
cancer. The search included in vitro, animal studies, mixed studies and comparative 
studies. Studies conducted on the effects of cannabidiol on breast cancer were identified 
in the following databases:  
 
 Pubmed 
 Science Direct 
 Springer Link 
 Ujoogle 
 Google scholar 
 Academic Search Complete 
 Lexis Nexus Academic 
 Proquest 
 
The search terms used to identify the relevant studies included: “Cannabidiol,” “CBD,” 
“Cannabis,” “breast cancer,” “carcinoma,” “carcinoma in situ,” “hemp oil,” and 
“tumour.” A combination of two terms was used in each search: one related to breast, the 
other to cannabidiol. These terms were used by themselves and in multiple combinations 
and different orders. Each search term contained one breast related term and one cannabis 
related term. Boolean operators were used in order to identify the relevant studies. The 
Boolean operators are words placed between search terms that either expand or limit the 
search criteria. The words used are “AND,” “OR” and “NOT” (Dillard, 2013).  
 
Table 3 Search strategy 
 
 Segment Detail 
A Intervention Cannabidiol, CBD, hemp oil, Cannabis 
B Disease medical term Breast cancer, carcinoma, carcinoma in situ, 
tumour 
C Combination A+B (in various combinations) 
 
3.2 Summary of modified CONSORT checklist findings 
The studies did not include randomisation although as previously stated this does not 
necessarily mean the studies are of poor quality (Krithikadatta et al., 2014). The studies 
had good experimental technique and methodological quality. However some vital 
information was missing in the reporting of some of the studies, such as was found in the 
study conducted by Elbaz et al. (2015). The lack of information does not necessarily 
indicate a poor study design. It is more so an error in reporting as this information should 
be available in the article. Authors should therefore follow CONSORT guidelines when 
publishing their findings.  
 
3.3 Results of studies 
CBD is cytotoxic to breast cancer cells and can inhibit cancer cell proliferation, 
invasiveness and metastases, in vitro, via multiple mechanisms and pathways. CBD is 
also selective in its cytotoxic effects and thus has little effect on normal breast cells. 
Some of the studies were able to exhibit these anticancer effects on aggressive breast 
cancer cell lines such as MDA-MB-231.  
 
3.4 Results of in vivo experiments 
CBD was found to inhibit tumour growth in mice and prevent metastases. CBD also 
inhibited macrophage recruitment thereby inhibiting tumour growth and metastases.  
 
3.5 Summary of ARRIVE guidelines checklist findings 
All the studies reviewed were poor quality with regards to the in vivo component. Little 
information was given with regards to the experiments conducted which decreased 
quality and increased the risk of bias. However the in vitro aspects of the studies were of 
higher quality and that is where the focus of the studies lay.  
 
3.6 Results of animal experiments 
CBD was able to inhibit tumour growth and metastatic potential in mice using multiple 
breast cancer cell lines including aggressive breast cancer cells.  
 
3.7 Mechanisms of CBDs anticancer effects 
Cancers grow via multiple pathways. The cancer usually starts off contained in the lining 
of a particular tissue. In breast cancer it is often the lining of the ducts and is thus called 
carcinoma in situ. This cancer is contained by the basement membrane. The cancer may 
continue to grow and eventually break through the basement membrane – it is now 
referred to as invasive cancer. The cancer requires the formation of new blood vessels 
(angiogenesis) in order to receive nutrients to continue growing – without an adequate 
blood flow cancers will be unable to grow due to lack of sufficient nutrients. If cancer 
cells continue to grow and spread, they may enter into the blood stream or lymphatic 
system. If this occurs, cancer cells can deposit into distant areas of the body; this is now 
called cancer metastasis (Cancer Research UK, 2014; Informed Health Online, 2016).  
 
CBD has been shown in these pre-clinical studies to act on various pathways of cancer 
growth and spread. This is accomplished via multiple modes of action. The studies 
included in this review illustrate how CBD acts on these different pathways thus 
inhibiting cancer cell growth and spread.   
 
3.8 CBDs role in cancer cell death (apoptosis) 
Choi et al. (2008) were able to demonstrate the ability of CBD to activate the apoptotic 
pathway in cancer cells via increasing LDH release in cancer cells (Choi et al., 2008).  
 
Caspase-3 is a major enzyme in the apoptotic cascade. CBD activates caspase-3. -8 and -
9 which may play a major role in CBD-induced cancer cell death (Choi et al., 2008). 
Choi et al. (2008) showed that CBD was able to inhibit the growth of cancer in a time 
and dose dependant manner. Shrivastava et al. (2011) also demonstrated CBDs ability to 
activate caspase-8 thereby inducing apoptosis (Shrivastava et al., 2011).  
 
CBD is able to promote cancer cell death in oestrogen receptor positive and oestrogen 
receptor negative breast cancer cells. CBD also selectively targets cancer cells while 
having little effect on normal cells (Shrivastava et al., 2011). Shrivastava et al. (2011) 
demonstrated CBDs ability to regulate apoptosis and autophagy thereby inducing cancer 
cell death in breast cancer cells. It was also found that CBD decreased the 
phosphorylation of AKT/mTOR and 4EBP1 while elevating cleaved PARP and LC3-II 
levels. The AKT/mTOR pathway can inhibit autophagy of cancer cells. By decreasing the 
phosphorylation of AKT/mTOR and 4EBP1 autophagy is increased. By elevating cleaved 
PARP and LC3-II levels, CBD was able to induce apoptosis and autophagy, suggesting 
that CBD may induce programmed cell death in breast cancer cells by regulating these 
pathways (Shrivastava et al., 2011).   
 
CBD is able to mediate apoptosis and autophagy by cleaving and translocating beclin-1 
to the mitochondria (Shrivastava et al., 2011).  
 
ROS plays a major role in program cell death. CBD is able to upregulate the generation 
of ROS in breast cancer cells thus leading to apoptosis (Shrivastava et al., 2011; Ligresti 
et al., 2006). CBDs ability to generate ROS may also decrease the expression of Id-1 thus 
decreasing cell proliferation and invasion (McAllister et al., 2011). 
 
Using a mouse model, Ligresti et al. (2006) showed that CBD and a CBD-enriched 
extract was able to decrease tumour size in mice (Ligresti et al., 2006).  
 
CBDs activation of the TRPV1 CB2 receptors, thereby increasing endocannabinoid 
concentration by acting as an antagonist, plays a partial role in cancer cell death in MDA-
MB-231 breast cancer cells (Ligresti et al., 2006).  
 
M2 macrophages are known to play a role in cancer cell growth and invasiveness through 
various mechanisms. CBD inhibits M2 macrophage and total macrophage populations 
(Ligresti et al., 2006).  
 
3.9 CBDs role in cancer cell spread and metastases 
Id-1 plays a crucial role in breast cancer progression and metastases. McAllister et al. 
(2007) demonstrated CBDs ability to inhibit Id-1 mRNA expression in breast cancer cells 
in an in vitro model, CBD may thereby decrease the aggressiveness and metastatic 
potential of the breast cancer cells (McAllister et al., 2007). 
 
CBD is able to upregulate ERK in MDA-MB-231 cancer cells thereby inhibiting Id-1 
expression and thus decreasing cancer cell growth and invasion (McAllister et al., 2011). 
 
MDA-MB-231 breast cancer cells were injected into athymic mice and growth and 
spread were examined. CBD was able to inhibit the formation of metastatic nodules in 
the lung of MDA-MB-231 breast cancer cells (Ligresti et al., 2006).  
 
By treating immune competent mouse models of breast cancer with CBD, McAllister et 
al. (2011) were able to significantly reduce primary tumour growth and metastases. The 
total number of and volume of secondary tumours in the mice also decreased when 
treated with CBD (McAllister et al., 2011).  
 
In the study conducted by Elbaz et al. (2015) there was a decrease in lung metastases and 
tumour proliferation in xenograft mouse models treated with CBD. 
 
Overexpression of EGFR is found in triple negative breast cancers and it associated with 
a poor prognosis. When triple negative breast cancer cell subtypes are treated with CBD 
in vitro, the EGF/EGFR pathway is suppressed thus inhibiting EGF-induced proliferation, 
migration and invasion. The EGF/EGFR pathway also activates the NF-kB pathway 
which has pro tumourigenic properties. CBD inhibits the activation of the NF-kB 
pathway thus inhibiting proliferation and metastatic potential (Elbaz et al., 2015).  
 
CBD inhibits actin stress fibres and focal adhesion formation, these play a role in cancer 
cell metastasis. CBDs ability to also downregulate MMP2 and MMP9 secretions in 
aggressive breast cancers further inhibits cancer cell invasion and metastases (Elbaz et 
al., 2015). 
 
3.10 CBDs role in angiogenesis 
CBD was shown to decrease tumour blood vessel formation in xenograft mouse models 
treated with CBD (Elbaz et al., 2015).  
 
The literature pertaining to cannabinoids in the treatment of breast cancer is limited, 
specifically with regards to clinical studies. Upon reviewing the above studies it was 
noted that there is a convincing argument to conduct further research into the therapeutic 
potential of Cannabis, and specifically CBD, in breast cancer. CBD has been shown to 
exert anticancer effects through multiple pathways in pre-clinical studies. CBD also has 
the advantage of being non-psychoactive and having little toxic effect on normal cells. 
This review attempted to encourage the further research into this area as it may prove to 
be a powerful anticancer therapy, whether used in isolation or as an adjuvant therapy. 
 
4. Conclusion  
 
The aim of the systematic review was to investigate and provide a summary and analysis 
of research that has been conducted on the effects of cannabidiol on breast cancer in pre-
clinical studies. 
 
Three in vitro studies and three mixed studies were reviewed. All studies showed CBDs 
ability to act as an anti-cancer agent in vitro and in vivo. The studies would have 
benefited from improved reporting as information regarding methodology was severely 
lacking in certain experiments and methods.  
 
The studies showed compelling evidence of CBDs anti-cancer activity in pre-clinical 
models of breast cancer. CBD exhibited anti-proliferative, anti-metastatic, anti-
angiogenic and pro-apoptotic properties when treating breast cancer in vitro and in in 
vivo animal models. This is due to CBDs ability to act on multiple pathways which target 
cancer cells but do not affect normal cells. However only pre-clinical trials exist, thus 
there is a need for human clinical trials. CBD may prove to be a significant therapy in the 
treatment of breast cancer due to its powerful anti-cancer effects and its safety profile.  
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